tirzepatide vs VK2735

NCT04184622 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial in 2,539 participants using percent change in body weight, the disease-defining endpoint for obesity, as the primary measure. All three tirzepatide doses produced significantly greater weight loss than placebo at 72 weeks.

NCT06828055 · Phase 2 · completed

This randomized, triple-blind, placebo-controlled Phase 2 trial (n=280) in adults with obesity found that oral VK2735 produced significantly greater weight loss than placebo at 13 weeks, up to 12.2% versus 1.3% (placebo-adjusted 10.9%, p<0.0001).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT03730662 · Phase 3 · completed

The study randomized 2,002 participants to tirzepatide or active insulin glargine control, but treatment was open-label rather than blinded. The primary endpoint was change in HbA1c, a laboratory surrogate rather than a hard clinical outcome; although the primary comparisons were statistically significant in favor of tirzepatide, this supports a moderate evidence grade.

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.